These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 16224157)

  • 21. Rescue therapy for lamivudine-resistant chronic hepatitis B: comparison between entecavir 1.0 mg monotherapy, adefovir monotherapy and adefovir add-on lamivudine combination therapy.
    Kim HJ; Park JH; Park DI; Cho YK; Sohn CI; Jeon WK; Kim BI
    J Gastroenterol Hepatol; 2010 Aug; 25(8):1374-80. PubMed ID: 20659226
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Entecavir 1.0mg monotherapy or entecavir plus adefovir dipivoxil for patients with lamivudine-resistant chronic hepatitis B had suboptimal response to lamivudine plus adefovir dipivoxil].
    Xing J; Han T; Liu L; Li Y; Li J; Li Y; Xiao SX
    Zhonghua Gan Zang Bing Za Zhi; 2011 Nov; 19(11):828-32. PubMed ID: 22433304
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Lamivudine compared with lamivudine and adefovir dipivoxil for the treatment of HBeAg-positive chronic hepatitis B.
    Sung JJ; Lai JY; Zeuzem S; Chow WC; Heathcote EJ; Perrillo RP; Brosgart CL; Woessner MA; Scott SA; Gray DF; Gardner SD
    J Hepatol; 2008 May; 48(5):728-35. PubMed ID: 18329126
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B.
    Marcellin P; Heathcote EJ; Buti M; Gane E; de Man RA; Krastev Z; Germanidis G; Lee SS; Flisiak R; Kaita K; Manns M; Kotzev I; Tchernev K; Buggisch P; Weilert F; Kurdas OO; Shiffman ML; Trinh H; Washington MK; Sorbel J; Anderson J; Snow-Lampart A; Mondou E; Quinn J; Rousseau F
    N Engl J Med; 2008 Dec; 359(23):2442-55. PubMed ID: 19052126
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Increased risk of adefovir resistance in patients with lamivudine-resistant chronic hepatitis B after 48 weeks of adefovir dipivoxil monotherapy.
    Lee YS; Suh DJ; Lim YS; Jung SW; Kim KM; Lee HC; Chung YH; Lee YS; Yoo W; Kim SO
    Hepatology; 2006 Jun; 43(6):1385-91. PubMed ID: 16729316
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Low resistance to adefovir combined with lamivudine: a 3-year study of 145 lamivudine-resistant hepatitis B patients.
    Lampertico P; Viganò M; Manenti E; Iavarone M; Sablon E; Colombo M
    Gastroenterology; 2007 Nov; 133(5):1445-51. PubMed ID: 17983801
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Entecavir 1mg versus combined lamivudine/adefovir dipivoxil in chronic HBV Egyptian patients resistant to LAM monotherapy, non-randomised controlled study.
    Maklad S; Doss W; El Din SS; Hassan K; Zeid AA
    Arab J Gastroenterol; 2014 Mar; 15(1):1-5. PubMed ID: 24630505
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Rescue therapy with adefovir in decompensated liver cirrhosis patients with lamivudine-resistant hepatitis B virus.
    Woo HY; Choi JY; Yoon SK; Suh DJ; Paik SW; Han KH; Um SH; Kim BI; Lee HJ; Cho M; Lee CK; Kim DJ; Hwang JS
    Clin Mol Hepatol; 2014 Jun; 20(2):168-76. PubMed ID: 25032183
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Factors associated with the virological response of lamivudine-resistant hepatitis B virus during combination therapy with adefovir dipivoxil plus lamivudine.
    Hosaka T; Suzuki F; Suzuki Y; Saitoh S; Kobayashi M; Someya T; Sezaki H; Akuta N; Arase Y; Ikeda K; Kumada H
    J Gastroenterol; 2007 May; 42(5):368-74. PubMed ID: 17530361
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Suppression of lamivudine-resistant B-domain mutants by adefovir dipivoxil in the woodchuck hepatitis virus model.
    Jacob JR; Korba BE; Cote PJ; Toshkov I; Delaney WE; Gerin JL; Tennant BC
    Antiviral Res; 2004 Aug; 63(2):115-21. PubMed ID: 15302140
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Study on the efficacy and safety of adefovir dipivoxil treatment in post-liver transplant patients with hepatitis B virus infection and lamivudine-resistant hepatitis B virus.
    Bárcena R; Del Campo S; Moraleda G; Casanovas T; Prieto M; Buti M; Moreno JM; Cuervas V; Fraga E; De la Mata M; Otero A; Delgado M; Loinaz C; Barrios C; Dieguez ML; Mas A; Sousa JM; Herrero JI; Muñoz R; Avilés JF; Gonzalez A; Rueda M
    Transplant Proc; 2005 Nov; 37(9):3960-2. PubMed ID: 16386596
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [The efficacy of adefovir dipivoxil monotherapy and the incidence of genotypic resistance to adefovir dipivoxil in patients with lamivudine-resistant chronic hepatitis B infection].
    Moon JH; Cho M; Yoon KT; Bae JH; Heo J; Kim GH; Kang DH; Song GA
    Korean J Hepatol; 2008 Dec; 14(4):503-12. PubMed ID: 19119245
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Severe exacerbation of chronic hepatitis B after emergence of lamivudine resistance in a cirrhotic patient: immediate switch to adefovir dipivoxil appears to be indicated.
    Wiegand J; Tischendorf JJ; Nashan B; Klempnauer J; Flemming P; Niemann P; Rohde P; Manns MP; Trautwein C; Tillmann HL
    Z Gastroenterol; 2004 Jan; 42(1):15-8. PubMed ID: 14997399
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Meta-analysis: oral anti-viral agents in adults with decompensated hepatitis B virus cirrhosis.
    Singal AK; Fontana RJ
    Aliment Pharmacol Ther; 2012 Mar; 35(6):674-89. PubMed ID: 22257108
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Efficacy and safety of adefovir dipivoxil 20 mg daily in HBeAg-positive patients with lamivudine-resistant hepatitis B virus and a suboptimal virological response to adefovir dipivoxil 10 mg daily.
    Hézode C; Chevaliez S; Bouvier-Alias M; Roudot-Thoraval F; Brillet R; Zafrani ES; Dhumeaux D; Pawlotsky JM
    J Hepatol; 2007 May; 46(5):791-6. PubMed ID: 17321635
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B.
    Marcellin P; Chang TT; Lim SG; Tong MJ; Sievert W; Shiffman ML; Jeffers L; Goodman Z; Wulfsohn MS; Xiong S; Fry J; Brosgart CL;
    N Engl J Med; 2003 Feb; 348(9):808-16. PubMed ID: 12606735
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Safety and efficacy of adefovir dipivoxil in patients co-infected with HIV-1 and lamivudine-resistant hepatitis B virus: an open-label pilot study.
    Benhamou Y; Bochet M; Thibault V; Calvez V; Fievet MH; Vig P; Gibbs CS; Brosgart C; Fry J; Namini H; Katlama C; Poynard T
    Lancet; 2001 Sep; 358(9283):718-23. PubMed ID: 11551579
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Randomized, three-arm study to optimize lamivudine efficacy in hepatitis B e antigen-positive chronic hepatitis B patients.
    Liang X; Cheng J; Sun Y; Chen X; Li T; Wang H; Jiang J; Chen X; Long H; Tang H; Yu Y; Sheng J; Chen S; Niu J; Ren H; Shi J; Dou X; Wan M; Jiang J; Xie Q; Shi G; Ning Q; Chen C; Tan D; Ma H; Sun J; Jia J; Zhuang H; Hou J
    J Gastroenterol Hepatol; 2015 Apr; 30(4):748-55. PubMed ID: 25352300
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Lamivudine plus adefovir or entecavir for patients with chronic hepatitis B resistant to lamivudine and adefovir.
    Heo NY; Lim YS; Lee HC; Chung YH; Lee YS; Suh DJ
    J Hepatol; 2010 Sep; 53(3):449-54. PubMed ID: 20646776
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Viral kinetics in patients with lamivudine-resistant hepatitis B during adefovir-lamivudine combination therapy.
    Mihm U; Gärtner BC; Faust D; Hofmann WP; Sarrazin C; Zeuzem S; Herrmann E
    J Hepatol; 2005 Aug; 43(2):217-24. PubMed ID: 15964093
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.